NCT01966822View on ClinicalTrials.gov

Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

HIV-1 Infection

Interventions

DRUG

Dolutegravir, 50mg every 24 hours

DRUG

Protease Inhibitor/ritonavir

Trial Locations (3)

28040

Hospital Clínico San Carlos, Madrid

08916

GermansTrias i Pujol Hospital, Badalona

08025

Hospital de la Santa Creu i Sant Pau, Barcelona

All Listed Sponsors

lead

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER

NCT01966822 - Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density | Biotech Hunter | Biotech Hunter